|
Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer Clinical research trials and Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer. Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer clinical trial. Human subjects frequently get the finest healthcare available for their Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer  Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer
Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer
For Condition: stage 4 breast cancer,recurrent breast cancer
Status: No longer recruiting
Sponsor(s): Ireland Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Drugs such as mesna may be effective in preventing some of the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy consisting of etoposide and ifosfamide given with mesna, and cisplatin in treating patients who have metastatic breast cancer.
Details: OBJECTIVES: - Determine the objective response rate in patients with metastatic breast cancer treated with etoposide, ifosfamide with mesna, and cisplatin. - Determine the tolerability and toxicity of this regimen in these patients. OUTLINE: Patients are stratified according to number of prior chemotherapy courses for metastatic disease (0 vs 1). Patients receive etoposide IV over 60-90 minutes, cisplatin IV over 30 minutes, and ifosfamide IV over 30 minutes on days 1-3. Mesna is administered IV over 15 minutes 30 minutes prior to and 4 hours after ifosfamide, then orally at 8 hours post infusion. Treatment continues every 28 days in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months. PROJECTED ACCRUAL: At least 36 patients (16 per stratum) will be accrued over 36 months.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically proven progressive metastatic breast cancer - Measurable disease - Any lesion measurable in 2 dimensions - Hepatic metastases if the sum of the measurements below the costal margin in the midclavicular line and the tip to the xiphoid process is greater than 5 cm during quiet respiration - Hepatic defects that are clearly measurable by radionuclide, CAT, or MRI scans - Bone metastases are not considered measurable disease - Evaluable disease allowed if measurable disease also present - No brain metastases, carcinomatous meningitis, or spinal cord compression - Hormone receptor status: - Not specified PATIENT CHARACTERISTICS: Age: - Not specified Menopausal status: - Not specified Performance status: - ECOG 0-2 Life expectancy: - At least 3 months Hematopoietic: - Hemoglobin at least 10 g/dL - WBC at least 4,000/mm3 - Platelet count at least 100,000/mm3 Hepatic: - Bilirubin no greater than 2.0 mg/dL Renal: - Creatinine no greater than 1.5 mg/dL - No bladder outlet obstruction Cardiovascular: - No symptomatic cardiovascular disease (e.g., congestive heart disease) or inability to tolerate a fluid load Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No active infection - No prior malignancies except adequately treated basal or squamous cell skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy: - No greater than 1 prior biologic response modifier treatment for metastatic disease Chemotherapy: - No greater than 1 prior chemotherapy regimen for metastatic disease allowed - Patients who relapsed during or within 6 months after adjuvant chemotherapy are considered to have failed 1 regimen - Patients who relapsed more than 6 months after adjuvant chemotherapy are considered to not have had a prior regimen - Greater than 4 weeks since prior chemotherapy (greater than 6 weeks for mitomycin or nitrosoureas) and recovered - No prior cisplatin, etoposide, or ifosfamide Endocrine therapy: - Prior medical or surgical hormonal therapy allowed Radiotherapy: - Prior radiation therapy to areas of measurable disease allowed if indicator lesion increased in size by greater than 25% after treatment - Recovered from effects of prior radiotherapy Surgery: - Recovered from effects of major surgery Other: - At least 7 days since prior nephrotoxic drugs (e.g., aminoglycosides, diuretics, lithium, intravenous contrast, or nonsteroidal antiinflammatory drugs)
Total Enrollment:
Location and Contact Information:
Overall Study Official:
ScotRemick, Study Chair, Ireland Cancer Center
Ireland Cancer Center
Cleveland, Ohio, 44106-5055
United States
Additional Information:
Study ID Numbers: CDR0000068196; CWRU-4196,BMS-CRWU-4196,NCI-G00-1854
Study Start Date:
Record last reviewed: April 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006260
Other Stage 4 Breast Cancer Studies:
1. Biological Therapy in Treating Women With Metastatic Breast Cancer
2. HER-2 Protein Vaccine in Treating Women With Breast Cancer
3. Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer
4. Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer
5. Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer
Related Studies:
Other stage 4 breast cancer Clinical Trials
Other Ohio Clinical Trials
Other Cleveland Clinical Trials
Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer
|
|
|
|
|
|
|
|
